Wheeler, C. M., Skinner, S. R., Del Rosario-Raymundo, M. R., Garland, S. M., Chatterjee, A., Lazcano-Ponce, E., Salmerón, J., McNeil, S., Stapleton, J. T., Bouchard, C., Martens, M. G., Money, D. M., Quek, S. C., Romanowski, B., Vallejos, C. S., ter Harmsel, B., Prilepskaya, V., Fong, K. L., Kitchener, H., Minkina, G., Lim, Y. K. T., Stoney, T., Chakhtoura, N., Cruickshank, M. E., Savicheva, A., da Silva, D. P., Ferguson, M., Molijn, A. C., Quint, W. G. V., Hardt, K., Descamps, D., Suryakiran, P. V., Karkada, N., Geeraerts, B., Dubin, G., Struyf, F., & , (n.d.). efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet infectious diseases, 16(10), 1154–1168. http://access.bl.uk/ark:/81055/vdc_100036192676.0x000026